Gene editing through microfluidic delivery
Gene editing can be performed by introducing gene-editing components into a cell by mechanical cell disruption. Related apparatus, systems, techniques, and articles are also described. The methods and systems of the invention solve the problem of intracellular delivery of gene editing components and gene editing complexes to target cells. The results described herein indicate that delivery of gene editing components, e.g., protein, ribonucleic acid (RNA), and deoxyribonucleic acid (DNA), by mechanical disruption of cell membranes leads to successful gene editing. Because intracellular delivery of gene editing materials is a current challenge, the methods provide a robust mechanism to engineer target cells without the use of potentially harmful viral vectors or electric fields.
1. A method for delivering a protein-nucleic acid complex into a cell comprising:
providing a cell in a suspension;
passing the suspension through a microfluidic channel that includes a cell-deforming constriction;
wherein a diameter of the constriction is 20-99% of a diameter of the cell and passage of the cell through the constriction induces perturbations of the cell membrane large enough for the protein-nucleic acid complex to pass through the perturbations in the membrane; and
contacting the cell with the protein-nucleic acid complex;
wherein the protein-nucleic acid complex passes through the perturbations in the membrane, thereby delivering the protein-nucleic acid complex into the cell, wherein a pressure of at least 10 psi is used to pass the suspension through the microfluidic channel.
2. The method of claim 1 , comprising contacting the cell with the protein-nucleic acid complex before the cell passes through the constriction.
3. The method of claim 2 , comprising contacting the cell with the protein-nucleic acid complex during passage of the cell through the constriction.
4. The method of claim 1 , comprising contacting the cell with the protein-nucleic acid complex after the cell passes through the constriction.
5. The method of claim 1 , wherein the protein-nucleic acid complex comprises gene editing components.
6. The method of claim 1 , wherein the protein-nucleic acid complex comprises a ribonucleoprotein (RNP).
7. The method of claim 5 , wherein the protein-nucleic acid complex comprises:
(a) a Cas protein; and
(b) a single guide RNA (sgRNA), or a CRISPR RNA (crRNA) and a trans-activating crRNA (tracrRNA).
8. The method of claim 7 , wherein the protein-nucleic acid complex comprises a ribonucleoprotein (RNP) comprising a Cas protein and an sgRNA and wherein the Cas protein and the sgRNA are complexed at a molar ratio between about 1:10 and about 10:1, respectively.
9. The method of claim 7 , wherein the Cas protein comprises a Cas9 protein.
10. The method of claim 1 , wherein said protein-nucleic acid complex comprises a first ribonucleoprotein (RNP) and a second RNP.
11. The method of claim 10 , wherein the first RNP and the second RNP both comprise nickase proteins.
12. The method of claim 11 , wherein the first RNP nicks a target sequence different from the target sequence of the second RNP.
13. The method of claim 1 , wherein said protein-nucleic acid complex comprises a TALEN protein, Zinc finger nuclease, mega nuclease, or Cre recombinase.
14. The method of claim 1 , wherein the protein-nucleic acid complex comprises:
(a) the nucleic acid molecule complexed with the protein via electrostatic attraction;
(b) the nucleic acid molecule wrapped around the protein;
(c) a DNA nucleic acid molecule and a histone protein;
(d) a ribonucleoprotein (RNP);
(e) a ribosome, an enzyme telomerase, a vault ribonucleoprotein, RNase P, hnRNP, or a small nuclear RNP (snRNP); or
(f) a chromosome comprising a protein.
15. The method of claim 1 , wherein the suspension further comprises a donor DNA.
16. The method of claim 15 , wherein the donor DNA is present in the suspension before the cell passes through the constriction.
17. The method of claim 1 , wherein the cell is a mammalian cell.
18. The method of claim 17 , wherein the cell is a human cell.
19. The method of claim 1 , wherein the diameter of the constriction is substantially about 20% to about 60% of the diameter of the cell.
20. The method of claim 1 , wherein the microfluidic channel is one of a plurality of parallel microfluidic channels in a microfluidic system.
21. The method of claim 20 , wherein the plurality of parallel microfluidic channels comprises at least about 2, 5, 10, 20, 25, 30, 40, 45, 50, 75, 100, 500, or 1,000 microfluidic channels.
22. The method of claim 1 , wherein the cell is a plurality of cells, wherein each cell is passed through one of a plurality of parallel microfluidic channels, and wherein each microfluidic channel of the plurality of parallel microfluidic channels includes a cell-deforming constriction.
23. The method of claim 1 , wherein the diameter of the constriction is about 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, 20, 2-10 μm, or 10-20 μm.
24. The method of claim 5 , wherein after the protein-nucleic acid complex is delivered to the cell,
(a) an expression of a target gene in the cell is reduced by at least about 5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 75, 80, 85, 90, 95, or 99% or more; or
(b) the cell is a plurality of cells and an expression of the target gene in the plurality of cells is reduced by at least about 5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 75, 80, 85, 90, 95, or 99% or more.
25. The method of claim 24 , wherein the expression of the target gene is reduced about 1, 2, 5, 12, 24, 48, 1-12, 6-12, 6-18, 12-24, or 1-24 hours after the protein-nucleic acid complex is delivered to the cell.
26. The method of claim 5 , wherein after the protein-nucleic acid complex is delivered to the cell,
(a) an expression of a target gene in the cell is increased by at least about 5, 10, 25, 50, 75, 100, 250, 500% or more; or
(b) the cell is a plurality of cells and an expression of the target gene in the plurality of cells is increased by at least about 5, 10, 25, 50, 75, 100, 250, 500% or more.
27. The method of claim 26 , wherein the expression of the target gene is increased about 1, 2, 5, 12, 24, 48, 1-12, 6-12, 6-18, 12-24, or 1-24 hours after the protein-nucleic acid complex is delivered to the cell.
28. The method of claim 1 , wherein said microfluidic channel comprises multiple cell-deforming constrictions.
29. The method of claim 1 , wherein the cell is contacted with the protein-nucleic acid complex for 0.0001 seconds to 20 minutes before, during, and/or after the cell passes through the constriction.
30. The method of claim 15 , wherein the cell is contacted with the protein-nucleic acid complex in the suspension comprising the donor DNA for 0.0001 seconds to 20 minutes before, during, and/or after the cell passes through the constriction.
31. The method of claim 1 , wherein a length of the constriction is about 10, 15, 20, 24, 30, 40, 50, 60, 70, 80, 90, 100, 10-40, 10-50, 10-60, or 10-100 μm.
32. The method of claim 1 , wherein a pressure of about 10, 20, 30, 40, 50, 60, 70, 80, 90, 100 or 10-100 psi is used to pass the suspension through the microfluidic channel.
33. The method of claim 1 , wherein the cell passes through the microfluidic channel at a speed of about 300, 400, 500, 600, 700, 800, 900, 100-300, 200-700, 250-400, 100-1000 mm/s, 1-1000 mm/s, 1 m/s, 2 m/s, 3 m/s, 4 m/s, 5 m/s, 6 m/s, 7 m/s, 8 m/s, 9 m/s, 10 m/s, 0.01-5 m/s, 5-10 m/s, or 0.01-10 m/s.
34. The method of claim 1 , wherein said microfluidic channel comprises a single cell-deforming constriction.
35. The method of claim 1 , wherein the perturbations of the cell include a maximum diameter of about 1-20, 1-600, 4, 5, 6, 7, 8, 9, 10, 12, 14, 16, 18, 20, 25, 50, 75, 100, 150, 200, 250, 300, 350, 400, 450, 500, or 600 nm.
36. The method of claim 1 , wherein perturbations of the cell having a maximum diameter of about 1-20, 1-600, 4, 5, 6, 7, 8, 9, 10, 12, 14, 16, 18, 20, 25, 50, 75, 100, 150, 200, 250, 300, 350, 400, 450, 500, or 600 nm persist on the cell for at least about 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10, or 1-10 minutes.
37. The method of claim 1 , wherein said microfluidic channel comprises multiple cell-deforming constrictions in parallel or in series.
38. The method of claim 15 , wherein the donor DNA is present in the suspension during passage of the cell through the constriction.
39. The method of claim 15 , wherein the donor DNA is present in the suspension after the cell passes through the constriction.
40. The method of claim 5 , wherein the protein-nucleic acid complex comprises:
(a) a Cpf1 protein; and
(b) a single guide RNA (sgRNA), or a CRISPR RNA (crRNA) and a trans-activating crRNA (tracrRNA).
41. The method of claim 40 , wherein the protein-nucleic acid complex comprises a ribonucleoprotein (RNP) comprising a Cpf1 protein and an sgRNA, and wherein the Cpf1 protein and the sgRNA are complexed at a molar ratio between about 1:10 and about 10:1, respectively.